Compare Gilead Sciences, Inc. (GILD) vs Nu Holdings Ltd (NU) Price & Performance

Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.

Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.

NU stock trades at $13.96, down 0.25% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with revenue growth from $8.3B in 2024 to $10.6B in 2025 and a net income margin of 26.72%. Recent news highlights expansion in Mexico, including banking approval and 15 million customers, signaling international growth potential. Analyst consensus is a Buy with a $14.98 price target, indicating 7% upside from current levels.

The outlook for NU remains positive due to robust earnings growth and Latin American market expansion, though risks include currency volatility and competitive pressures. With a P/E of 21.41 and ROE of 30.04%, the stock offers value if execution continues. Investors should weigh strong cash flow trends against macroeconomic headwinds in emerging markets.